<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1601">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140317</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0342</org_study_id>
    <nct_id>NCT05140317</nct_id>
  </id_info>
  <brief_title>5 Years Follow up of the SAPIEN 3 Valve From the DIRECTAVI Trial</brief_title>
  <acronym>DIRECTAVILONG</acronym>
  <official_title>5 Years Hemodynamic and Clinical Follow-up of the SAPIEN 3 Transcatheter Heart Valve According to the Implantation Strategy: Insight From the Randomized DIRECTAVI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A strategy of Transcatheter Aortic Valve Replacement (TAVR) without balloon predilatation has&#xD;
      shown to be feasible in routine in observational studies and in two recent randomized trial&#xD;
      including the DIRECTAVI trial. Whether the initial implantation strategy may impact the&#xD;
      long-term trans catheter heart valve (THV) performances and patient outcomes remains unknown&#xD;
      to date. The Investigators therefore aimed to evaluate the 5-years impact of the implantation&#xD;
      strategy on THV hemodynamic performances and clinical outcomes in patients included in the&#xD;
      DIRECTAVI trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients (n=236) included in the DIRECTAVI randomized trial conducted between May 2016 to&#xD;
      May 2018 will be prospectively assessed for up to 5 years follow-up . The DIRECTAVI&#xD;
      prospective, randomized, single-center, open-label trial, demonstrated the non-inferiority of&#xD;
      a &quot;direct TAVR&quot; strategy using the third-generation balloon-expandable Edwards SAPIEN 3&#xD;
      device (Edwards Lifesciences, Irvine, CA, USA)&#xD;
&#xD;
      A systematic echographic follow-up will be performed in all patients enrolled in the&#xD;
      DIRECTAVI trial at the longest follow -up obtained after TAVR between 2021 and 2022. Clinical&#xD;
      follow-up will be obtained with a brief patient clinical questionnaire or by phone by&#xD;
      patients' cardiologist.&#xD;
&#xD;
      Serial Echographic follow-up will be obtained by patients' cardiologist except for the latest&#xD;
      follow-up echocardiography (primary end point) performed in the reference center at&#xD;
      Montpellier University hospital by two experienced cardiologists specialized in valvular&#xD;
      echography to avoid inter operator variability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of patients without THV dysfunction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>the incidence of patients without THV dysfunction according to the implantation strategy group (direct implantation vs ballon predilatation) at the latest follow-up available (up to 5 years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the incidence of patients without correct hemodynamic performance</measure>
    <time_frame>up to 5 years</time_frame>
    <description>the incidence of patients without correct hemodynamic performance according to the implantation strategy group (direct implantation vs ballon predilatation) at the latest follow-up available (up to 5 years)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Coronary Syndrome</condition>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>The direct stargegy group included patients with implanation of the THV without predilatation The reference group included patients with direct implanation of tne THV withour predilaation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>the echographists were blinded regarding the groups of the patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter heart valve implantation with or withour predilatatation</intervention_name>
    <description>long term up to 5 years echographic and clinical follow up</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients included in the DIRECTAVI trial&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Older than 18 years old.&#xD;
&#xD;
          -  patients included in the DIRECTAVI trial&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Patients not living in France&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Leclercq, PU PH</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Leclercq, PU PH</last_name>
    <phone>4.67.33.67.33</phone>
    <phone_ext>33</phone_ext>
    <email>f-leclercq@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Leclercq, PUPH</last_name>
      <phone>04.67.33.67.33</phone>
      <phone_ext>33</phone_ext>
      <email>f-leclercq@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patients included in the directavi trial</keyword>
  <keyword>TAVR Hemodynamic performances long term follow up</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

